A longtime Laura Shawver fan calls the serial entrepreneur back to the helm of a biotech upstart
Just a few months after nabbing an $88 million windfall in her payout for Sanofi’s $2.5 billion Synthorx buyout, serial biotech entrepreneur Laura Shawver is back at the helm of another startup.
Seattle-based Silverback Therapeutics recruited Shawver to head the team, just weeks after founding CEO — and OrbiMed partner — Peter Thompson was heralding a $78 million raise to fund their work on a next-gen antibody drug conjugate. Now Shawver will be in charge of steering that program to the clinic, where it will be tested in HER2 positive cancers.
Before Synthorx, Shawver completed a stint at Cleave, where she also had the backing of co-founder Thompson. And Thompson was an investor and board member of Synthorx as well, maintaining a longstanding relationship that has helped fuel her career up and down the West Coast biotech community.
“With her range of strategic expertise, demonstrated success raising capital, scientific acumen, and broad drug development experience, Laura is the perfect fit for Silverback,” Thompson said in a prepared statement.